Robert Wessman on a mission: to make Alvogen a major generics player
This article was originally published in Scrip
Executive Summary
Robert Wessman, the ex-CEO of Actavis, is on a mission. Having helped build up that company over nearly 10 years into a leading global generics company, he wants to repeat the process, but this time he wants to be involved right from the start.